PACB Pacific Biosciences Of California Inc

Price (delayed)

$5.19

Market cap

$1.39B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.21

Enterprise value

$2.14B

Pacific Biosciences of California, Inc. is empowering life scientists with highly accurate long-read sequencing. The company's innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a ...

Highlights
The quick ratio has soared by 134% YoY and by 62% from the previous quarter
The revenue has soared by 56% YoY and by 18% QoQ
The company's equity rose by 25% YoY but it fell by 8% QoQ
The gross margin has contracted by 31% YoY and by 8% from the previous quarter

Key stats

What are the main financial stats of PACB
Market
Shares outstanding
267.95M
Market cap
$1.39B
Enterprise value
$2.14B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.98
Price to sales (P/S)
6.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.69
Earnings
Revenue
$200.52M
EBIT
-$303.82M
EBITDA
-$277.28M
Free cash flow
-$268.02M
Per share
EPS
-$1.21
Free cash flow per share
-$1.06
Book value per share
$2.62
Revenue per share
$0.79
TBVPS
$3.26
Balance sheet
Total assets
$1.75B
Total liabilities
$1.04B
Debt
$933.44M
Equity
$701.3M
Working capital
$647.02M
Liquidity
Debt to equity
1.33
Current ratio
7.81
Quick ratio
7.03
Net debt/EBITDA
-2.72
Margins
EBITDA margin
-138.3%
Gross margin
26.3%
Net margin
-153%
Operating margin
-159.3%
Efficiency
Return on assets
-16.6%
Return on equity
-43.8%
Return on invested capital
-21.3%
Return on capital employed
-18.4%
Return on sales
-151.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PACB stock price

How has the Pacific Biosciences Of California stock price performed over time
Intraday
-6.15%
1 week
1.57%
1 month
-23.22%
1 year
-40.82%
YTD
-47.09%
QTD
-47.09%

Financial performance

How have Pacific Biosciences Of California's revenue and profit performed over time
Revenue
$200.52M
Gross profit
$52.78M
Operating income
-$319.41M
Net income
-$306.74M
Gross margin
26.3%
Net margin
-153%
The revenue has soared by 56% YoY and by 18% QoQ
The net margin is up by 38% year-on-year and by 16% since the previous quarter
PACB's operating margin is up by 33% year-on-year and by 14% since the previous quarter
The gross margin has contracted by 31% YoY and by 8% from the previous quarter

Growth

What is Pacific Biosciences Of California's growth rate over time

Valuation

What is Pacific Biosciences Of California stock price valuation
P/E
N/A
P/B
1.98
P/S
6.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.69
The EPS has grown by 14% YoY and by 4.7% from the previous quarter
The P/B is 79% below the 5-year quarterly average of 9.3 and 49% below the last 4 quarters average of 3.9
The company's equity rose by 25% YoY but it fell by 8% QoQ
The price to sales (P/S) is 71% lower than the 5-year quarterly average of 22.8 and 62% lower than the last 4 quarters average of 17.2
The revenue has soared by 56% YoY and by 18% QoQ

Efficiency

How efficient is Pacific Biosciences Of California business performance
The ROS has grown by 35% YoY and by 16% from the previous quarter
The ROE has grown by 9% YoY and by 6% from the previous quarter
The company's return on invested capital fell by 8% YoY but it rose by 3.6% QoQ
PACB's ROA is up by 2.4% YoY

Dividends

What is PACB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PACB.

Financial health

How did Pacific Biosciences Of California financials performed over time
The company's total assets is 67% higher than its total liabilities
The company's current ratio has surged by 141% YoY and by 63% QoQ
The quick ratio has soared by 134% YoY and by 62% from the previous quarter
The debt is 33% greater than the equity
The company's equity rose by 25% YoY but it fell by 8% QoQ
The company's debt to equity fell by 21% YoY but it rose by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.